Effwa Infra & Research Fund Raise of ₹51.27 Cr

Effwa Infra & Research Investor Presentation: Key Takeaways

H1 FY27 deck discloses no revenue, PAT or EBITDA figures. Business is ZLD/ETP EPC; 92.4% of FY26 revenue from ZLD; CRISIL BBB+/Stable.

Effwa Infra & Research H1 FY27 Results: Net Profit ₹15.1 Cr, Up 49.5% YoY

Effwa Infra & Research approved un-audited financial results for the half year ended September 30, 2026. Revenue from operations rose to Rs.13,064.90 lakhs with post-tax profit of Rs.1,509.68 lakhs.

Key figure

Net profit ₹15.1 Cr · +49.5% YoY

Effwa Infra & Research Other Announcement

Effwa Infra & Research Limited has informed the exchange about the non-applicability of Corporate Governance provisions for the quarter ended September 30, 2026.

Effwa Infra & Research Annual General Meeting

Effwa Infra & Research held its 13th Annual General Meeting on September 30, 2026. Shareholders approved all six resolutions, including the final dividend declaration.

Effwa Infra & Research Annual General Meeting

Effwa Infra & Research Ltd. announced its 13th AGM on September 30, 2026. The record date for the final dividend is fixed for September 22, 2026.

Effwa Infra & Research Other Announcement

Effwa Infra & Research Limited informed the exchange that Corporate Governance provisions are not applicable to the company for the quarter ended June 30, 2026.

Rajkot Investment Trust Fund Raise of ₹48 Cr

Rajkot Investment Trust's board approved a Rs 48 Crore rights issue of equity shares. Pricing and record date will be set later by a committee.

Value

₹48.00 Cr

U Y Fincorp Fund Raise of ₹187.2 Cr

U.Y. Fincorp's board approved preferential issues of warrants and equity shares aggregating Rs 187.17 Crore. The issue is subject to shareholder and regulatory approvals.

Value

₹187.2 Cr

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026